⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
AZN News
AstraZeneca PLC
Questex’s Fierce Life Sciences Announces the 2026 Partnerships with Sites Summit Agenda
globenewswire.com
LLY
BIIB
AZN
BMY
MRK
TEVA
NYSE Content Update: AstraZeneca Celebrates Largest Transfer in NYSE History
prnewswire.com
SSMR
AZN
FTRA
ICE
Form 8-K
sec.gov
TPST
VRTX
AMGN
AZN
BMY
FLEX
IgE Receptor Antagonists Clinical Trial Pipeline Analysis: 12+ Key Companies Shaping the Future of IgE Receptor Antagonists Therapeutics | DelveInsight
globenewswire.com
AMRX
ARX
GSK
AZN
SNY
NVS
MRK
REGN
JNJ
PFE
BMY
LLY
VRTX
AMGN
ABBV
GILD
BIIB
CSL
AQST
RAPT
ALGT
Camizestrant Combination Delayed Time to First Progression by 55% and to Second Progression by 37% in Patients With Advanced HR-positive Breast Cancer With an Emergent ESR1 Tumor Mutation in SERENA-6 Trial
businesswire.com
AZN
DigiCert Research Reveals Major Certificate Visibility Blind Spot for Enterprises
globenewswire.com
MSFT
GOOG
AMZN
IBM
ORCL
CSCO
DELL
HPQ
INTC
QCOM
NVDA
AMD
AVGO
MU
AMAT
LRCX
KLAC
ADI
TXN
NXPI
MRVL
SNPS
CDNS
ADSK
CRM
ACN
INFY
SAP
PANW
CRWD
OKTA
FTNT
DDOG
NOW
MCHP
ON
LULU
BBY
COST
HD
LOW
TJX
MDT
AMGN
GILD
BMY
PFE
MRK
JNJ
ABBV
LLY
BIIB
REGN
VRTX
AZN
SNOW
SMCI
PLTR
AI
GOOGL
Laboratory Equipment Services Market by Service Type, Service Provider, Equipment Type, Contract Type - Global Forecast to 2030
globenewswire.com
A
TMO
AZN
Paradigm Health Implements New Clinical Trial Solution to Support Observational Study Presented at ASCO
prnewswire.com
AZN
IMFINZI® (durvalumab) plus IMJUDO® (tremelimumab-actl) combined with lenvatinib and TACE reduced the risk of disease progression or death by 30% in embolization-eligible unresectable liver cancer in EMERALD-3 Phase III trial
businesswire.com
AZN
BioInvent to Host a KOL Event in Stockholm on June 11, 2026, to Discuss Updated BI-1206 & BI-1808 Data in Hematology
accessnewswire.com
AZN